Contact Congress about S. 4885: Shandra Eisenga Human Cell and Tissue Product Safety Act

The FDA would get stronger tools to oversee human cell and tissue products. Clinics and companies could face fines for some rule-breaking. Patients, doctors, and businesses would also get more public information from FDA.

Modern Action explains what the legislation does, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.

Shandra Eisenga Human Cell and Tissue Product Safety Act is a Senate bill in committee. The latest recorded action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Latest action on S. 4885: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Who this affects: This bill mainly affects clinics, companies, tissue establishments, researchers, patients, and health care workers involved with human cell and tissue products. It could change how closely businesses follow FDA rules, how much public information patients and doctors can see, and how future rules for stem cell and other cell-based therapies are shaped.

Why this matters: Human cell and tissue products can raise real safety questions, and this bill would give the FDA more ways to push rule-following. It could also make the rules easier to see and discuss. The practical effect is uncertain because much would depend on future FDA guidance, workshops, reports, and how clinics and companies respond.

Key provisions in S. 4885

• HHS must support education for health care workers and other professionals on organ, tissue, and eye donation. The materials must include evidence-based ways to talk with patients and families, plus information on donor screening tests.
• The bill creates money penalties for breaking certain FDA safety and quality rules for human cell and tissue products. These are products regulated under the Public Health Service Act section that covers disease-control rules for these products.
• Fines could reach $20,000 for each violation. If the violation keeps going after written notice, another $20,000 per day could apply, plus the retail value of the products involved. One legal proceeding could not exceed $10 million in penalties.
• The FDA must publish clear materials about the Tissue Reference Group. That FDA group gives advice on how human cell and tissue products are regulated. The materials must explain how to get timely and accurate recommendations.
• For four years, FDA must post yearly public data starting within one year after the bill becomes law. The data must cover registered human cell and tissue establishments, FDA inspections, how those inspections compare with blood establishment inspections, Tissue Reference Group questions, and average response times.

How Modern Action helps you take action on S. 4885

You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.

Questions people ask about S. 4885

What is S. 4885?

The FDA would get stronger tools to oversee human cell and tissue products. Clinics and companies could face fines for some rule-breaking. Patients, doctors, and businesses would also get more public information from FDA.

How do I support or oppose S. 4885?

Choose support, oppose, or ask for changes on Modern Action. The action flow drafts the message for you and keeps the wording tied to this bill.

Who should I contact about S. 4885?

Modern Action uses your location to route the action to the congressional offices relevant to the bill and your representation.

How does Modern Action help me act on S. 4885?

Modern Action gives you bill-specific context, lets you choose support, opposition, or changes, and drafts a message from your position and reasons.